Endocrinology and Metabolism

Brief Report

Diabetes, Obesity and Metabolism
Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies: Dimitrios Patoulias, Michael Doumas; Endocrinol Metab. 2021;36(4):904-908. Published online July 27, 2021; DOI: https://doi.org/10.3803/EnM.2021.1048

10,267 View
212 Download
19 Citations

Abstract PDF Supplementary Material PubReader ePub

The coronavirus disease 2019 (COVID-19) pandemic remains an unbeaten enemy. Unfortunately, no targeted treatment option is available. Patients with type 2 diabetes mellitus (T2DM) have increased odds for severe or fatal disease, as demonstrated in recent observational studies. There is an ongoing discussion regarding the impact of different antidiabetic drug classes on outcomes of interest among affected subjects. Dipeptidyl peptidase-4 (DPP-4) inhibitors have been placed at the epicenter, since the DPP-4 enzyme seems to be implicated in the disease pathogenesis. Herein we present an updated meta-analysis of observational studies addressing the risk of COVID-19 death among patients with T2DM on prior DPP-4 inhibitor treatment. We pooled data from 10 observational studies, showing that DPP-4 inhibitors produce a non-significant decrease in the risk for COVID-19-related death. However, when administered in the inpatient setting, DPP-4 inhibitors decrease the risk for COVID-19-related death by 50%. Ongoing randomized controlled trials will shed further light.

Citations

Citations to this article as recorded by

Noninsulin‐based antihyperglycemic medications in patients with diabetes and COVID‐19: A systematic review and meta‐analysis
Mahmoud Nassar, Hazem Abosheaishaa, Awadhesh Kumar Singh, Anoop Misra, Zachary Bloomgarden
Journal of Diabetes.2023; 15(2): 86. CrossRef
Effects of novel glucose-lowering drugs on the COVID-19 patients with diabetes: A network meta-analysis of clinical outcomes
Yang Yang, Ling Zhao, Yeying Wang, Chengjiang Liu, Tingyu Ke
International Journal of Diabetes in Developing Countries.2023;[Epub] CrossRef
COVID-19 and metabolic syndrome
Harsha Dissanayake
Best Practice & Research Clinical Endocrinology & Metabolism.2023; 37(4): 101753. CrossRef
Current management of diabetes patients with COVID-19
Arup Kumar Misra, Gaurav Rangari, Madhavrao C, Sushil Sharma
Expert Review of Endocrinology & Metabolism.2023; 18(2): 199. CrossRef
Current management of diabetes patients with COVID-19
Arup Kumar Misra, Gaurav Rangari, Madhavrao C, Sushil Sharma
Expert Review of Endocrinology & Metabolism.2023; : 1. CrossRef
Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes
Andreana Foresta, Luisa Ojeda-Fernandez, Giulia Macaluso, Maria Carla Roncaglioni, Mauro Tettamanti, Ida Fortino, Olivia Leoni, Stefano Genovese, Marta Baviera
Clinical Therapeutics.2023; 45(4): e115. CrossRef
DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes
Snehasish Nag, Samanwita Mandal, Oindrila Mukherjee, Suprabhat Mukherjee, Rakesh Kundu
Future Virology.2023; 18(5): 321. CrossRef
DrugRep-HeSiaGraph: when heterogenous siamese neural network meets knowledge graphs for drug repurposing
Zahra Ghorbanali, Fatemeh Zare-Mirakabad, Najmeh Salehi, Mohammad Akbari, Ali Masoudi-Nejad
BMC Bioinformatics.2023;[Epub] CrossRef
Immunomodulatory activity of dipeptidyl peptidase‐4 inhibitors in immune‐related diseases
Marija Drakul, Miodrag Čolić
European Journal of Immunology.2023;[Epub] CrossRef
Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 — A systematic review and meta-analysis
Ahmad Fariz Malvi Zamzam Zein, Wilson Matthew Raffaello
Primary Care Diabetes.2022; 16(1): 162. CrossRef
Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis
Nam Nhat Nguyen, Dung Si Ho, Hung Song Nguyen, Dang Khanh Ngan Ho, Hung-Yuan Li, Chia-Yuan Lin, Hsiao-Yean Chiu, Yang-Ching Chen
Metabolism.2022; 131: 155196. CrossRef
The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis
Yidan Chen, Xingfei Lv, Sang Lin, Mohammad Arshad, Mengjun Dai
Frontiers in Endocrinology.2022;[Epub] CrossRef
Type 2 Diabetes Mellitus and COVID-19: A Narrative Review
Cristina Rey-Reñones, Sara Martinez-Torres, Francisco M. Martín-Luján, Carles Pericas, Ana Redondo, Carles Vilaplana-Carnerero, Angela Dominguez, María Grau
Biomedicines.2022; 10(9): 2089. CrossRef
Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
Alba Sebastián-Martín, Belén G. Sánchez, José M. Mora-Rodríguez, Alicia Bort, Inés Díaz-Laviada
Biomedicines.2022; 10(8): 2026. CrossRef
Non-Insulin Novel Antidiabetic Drugs Mechanisms in the Pathogenesis of COVID-19
Teodor Salmen, Valeria-Anca Pietroșel, Bianca-Margareta Mihai, Ioana Cristina Bica, Claudiu Teodorescu, Horia Păunescu, Oana Andreia Coman, Doina-Andrada Mihai, Anca Pantea Stoian
Biomedicines.2022; 10(10): 2624. CrossRef
Antidiabetic treatment and COVID-19 Outcomes: A population-based cohort study in primary health care in Catalonia during the first wave of the pandemic
Dan Ouchi, Carles Vilaplana-Carnerero, Vanessa de Dios, Maria Giner-Soriano, Rosa Morros
Primary Care Diabetes.2022; 16(6): 753. CrossRef
Immunotropic effects of hypoglycemic agents on coronavirus infection: a view from the perspective of pharmacogenetics
Konstantin G. Gurevich, Yulia A. Sorokina, Alexander L. Urakov, Snezhana D. Sinyushkina, Maria I. Pryazhnikova, Alyona V. Gorinova, Lyubov V. Lovtsova, Olga V. Zanozina
Reviews on Clinical Pharmacology and Drug Therapy.2022; 20(3): 269. CrossRef
Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control
Niya Narayanan, Dukhabandhu Naik, Jayaprakash Sahoo, Sadishkumar Kamalanathan
World Journal of Virology.2022; 11(6): 399. CrossRef
Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression
Maria Ida Maiorino, Miriam Longo, Lorenzo Scappaticcio, Giuseppe Bellastella, Paolo Chiodini, Katherine Esposito, Dario Giugliano
Cardiovascular Diabetology.2021;[Epub] CrossRef

Original Articles

Clinical Study
Clinical Outcomes of COVID-19 Patients with Type 2 Diabetes: A Population-Based Study in Korea: Ji Hong You, Sang Ah Lee, Sung-Youn Chun, Sun Ok Song, Byung-Wan Lee, Dae Jung Kim, Edward J. Boyko; Endocrinol Metab. 2020;35(4):901-908. Published online December 10, 2020; DOI: https://doi.org/10.3803/EnM.2020.787

6,332 View
228 Download
18 Citations

Abstract PDF Supplementary Material PubReader ePub

Background
The aim of this study was to evaluate clinical outcomes in coronavirus disease 2019 (COVID-19) positive patients with type 2 diabetes compared to those without diabetes in Korea.
Methods
We extracted claims data for patients diagnosed with COVID-19 from the National Health Insurance Service database in Korea from January 20, 2020 to March 31, 2020. We followed up this cohort until death from COVID-19 or discharge from hospital.
Results
A total of 5,473 patients diagnosed with COVID-19 were analyzed, including 495 with type 2 diabetes and 4,978 without diabetes. Patients with type 2 diabetes were more likely to be treated in the intensive care unit (ICU) (P<0.0001). The incidence of inhospital mortality was higher in patients with type 2 diabetes (P<0.0001). After adjustment for age, sex, insurance status, and comorbidities, odds of ICU admission (adjusted odds ratio [OR], 1.59; 95% confidence interval [CI], 1.02 to 2.49; P=0.0416) and in-hospital mortality (adjusted OR, 1.90; 95% CI, 1.13 to 3.21; P=0.0161) among patients with COVID-19 infection were significantly higher in those with type 2 diabetes. However, there was no significant difference between patients with and without type 2 diabetes in ventilator, oxygen therapy, antibiotics, antiviral drugs, antipyretics, and the incidence of pneumonia after adjustment.
Conclusion
COVID-19 positive patients with type 2 diabetes had poorer clinical outcomes with higher risk of ICU admission and in-hospital mortality than those without diabetes. Therefore, medical providers need to consider this more serious clinical course when planning and delivering care to type 2 diabetes patients with COVID-19 infection.

Citations

Citations to this article as recorded by

Risk for Newly Diagnosed Type 2 Diabetes Mellitus after COVID-19 among Korean Adults: A Nationwide Matched Cohort Study
Jong Han Choi, Kyoung Min Kim, Keeho Song, Gi Hyeon Seo
Endocrinology and Metabolism.2023; 38(2): 245. CrossRef
The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence
Mykhailo Buchynskyi, Iryna Kamyshna, Valentyn Oksenych, Nataliia Zavidniuk, Aleksandr Kamyshnyi
Viruses.2023; 15(5): 1072. CrossRef
Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis
Sabrina Schlesinger, Alexander Lang, Nikoletta Christodoulou, Philipp Linnerz, Kalliopi Pafili, Oliver Kuss, Christian Herder, Manuela Neuenschwander, Janett Barbaresko, Michael Roden
Diabetologia.2023; 66(8): 1395. CrossRef
Diabetes and deaths of COVID-19 patients: Systematic review of meta-analyses
Aakriti Garg, Mahesh Kumar Posa, Anoop Kumar
Health Sciences Review.2023; 7: 100099. CrossRef
Cardiometabolic Risk Factors and COVID-19 Outcomes in the Asia-Pacific Region: A Systematic Review, Meta-analysis and Meta-regression of 84,011 Patients
Ru Ying Fong, Annie Lee, Fei Gao, Jonathan Jiunn Liang Yap, Khung Keong Yeo
Journal of Asian Pacific Society of Cardiology.2023;[Epub] CrossRef
Pituitary Diseases and COVID-19 Outcomes in South Korea: A Nationwide Cohort Study
Jeonghoon Ha, Kyoung Min Kim, Dong-Jun Lim, Keeho Song, Gi Hyeon Seo
Journal of Clinical Medicine.2023; 12(14): 4799. CrossRef
Factors influencing the severity of COVID-19 course for patients with diabetes mellitus in tashkent: a retrospective cohort study
A. V. Alieva, A. A. Djalilov, F. A. Khaydarova, A. V. Alimov, D. Z. Khalilova, V. A. Talenova, N. U. Alimova, M. D. Aripova, A. S. Sadikova
Obesity and metabolism.2023; 20(2): 92. CrossRef
Genetic Predictors of Comorbid Course of COVID-19 and MAFLD: A Comprehensive Analysis
Mykhailo Buchynskyi, Valentyn Oksenych, Iryna Kamyshna, Sandor G. Vari, Aleksandr Kamyshnyi
Viruses.2023; 15(8): 1724. CrossRef
Anti-SARS-CoV-2 antibody levels predict outcome in COVID-19 patients with type 2 diabetes: a prospective cohort study
Sylvia Mink, Christoph H. Saely, Andreas Leiherer, Matthias Frick, Thomas Plattner, Heinz Drexel, Peter Fraunberger
Scientific Reports.2023;[Epub] CrossRef
Reasons for Hospitalization Among Australians With Type 1 or Type 2 Diabetes and COVID-19
Dunya Tomic, Jonathan E. Shaw, Dianna J. Magliano
Canadian Journal of Diabetes.2023;[Epub] CrossRef
Two years of SARS-CoV-2 infection (2019–2021): structural biology, vaccination, and current global situation
Waqar Ahmad, Khadija Shabbiri
The Egyptian Journal of Internal Medicine.2022;[Epub] CrossRef
Baseline haemoglobin A1c and the risk of COVID‐19 hospitalization among patients with diabetes in the INSIGHT Clinical Research Network
Jea Young Min, Nicholas Williams, Will Simmons, Samprit Banerjee, Fei Wang, Yongkang Zhang, April B. Reese, Alvin I. Mushlin, James H. Flory
Diabetic Medicine.2022;[Epub] CrossRef
The Role of Diabetes and Hyperglycemia on COVID-19 Infection Course—A Narrative Review
Evangelia Tzeravini, Eleftherios Stratigakos, Chris Siafarikas, Anastasios Tentolouris, Nikolaos Tentolouris
Frontiers in Clinical Diabetes and Healthcare.2022;[Epub] CrossRef
Impact of Type 2 Diabetes Mellitus on the Incidence and Outcomes of COVID-19 Needing Hospital Admission According to Sex: Retrospective Cohort Study Using Hospital Discharge Data in Spain, Year 2020
Jose M. de Miguel-Yanes, Rodrigo Jimenez-Garcia, Javier de Miguel-Diez, Valentin Hernández-Barrera, David Carabantes-Alarcon, Jose J. Zamorano-Leon, Ricardo Omaña-Palanco, Ana Lopez-de-Andres
Journal of Clinical Medicine.2022; 11(9): 2654. CrossRef
The burden and risks of emerging complications of diabetes mellitus
Dunya Tomic, Jonathan E. Shaw, Dianna J. Magliano
Nature Reviews Endocrinology.2022; 18(9): 525. CrossRef
A Comprehensive Analysis of Chinese, Japanese, Korean, US-PIMA Indian, and Trinidadian Screening Scores for Diabetes Risk Assessment and Prediction
Norma Latif Fitriyani, Muhammad Syafrudin, Siti Maghfirotul Ulyah, Ganjar Alfian, Syifa Latif Qolbiyani, Muhammad Anshari
Mathematics.2022; 10(21): 4027. CrossRef
New-Onset Diabetes Mellitus Presenting As Diabetic Ketoacidosis in Patients With COVID-19: A Case Series
Aysha Sarwani, Mahmood Al Saeed, Husain Taha, Rawdha M Al Fardan
Cureus.2021;[Epub] CrossRef
The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence?
Leszek Czupryniak, Dror Dicker, Roger Lehmann, Martin Prázný, Guntram Schernthaner
Cardiovascular Diabetology.2021;[Epub] CrossRef

Diabetes, Obesity and Metabolism
High Fibrosis-4 Index Is Related with Worse Clinical Outcome in Patients with Coronavirus Disease 2019 and Diabetes Mellitus: A Multicenter Observational Study: Sung-Woo Kim, Jae-Han Jeon, Jun Sung Moon, Mi Kyung Kim; Endocrinol Metab. 2021;36(4):800-809. Published online August 20, 2021; DOI: https://doi.org/10.3803/EnM.2021.1040

4,484 View
173 Download
5 Citations

Abstract PDF PubReader ePub

Background
Based on recent evidence on the importance of the presence of diabetes mellitus (DM) and fibrosis-4 (FIB-4) index in coronavirus disease 2019 (COVID-19) mortality, we analyzed whether these factors could additively predict such mortality.
Methods
This multicenter observational study included 1,019 adult inpatients admitted to university hospitals in Daegu. The demographic and laboratory findings, mortality, prevalence of severe disease, and duration of quarantine were compared between patients with and without DM and/or a high FIB-4 index. The mortality risk and corresponding hazard ratio (HR) were analyzed using the Kaplan-Meier method and Cox proportional hazard models.
Results
The patients with DM (n=217) exhibited significantly higher FIB-4 index and mortality compared to those without DM. Although DM (HR, 2.66; 95% confidence interval [CI], 1.63 to 4.33) and a high FIB-4 index (HR, 4.20; 95% CI, 2.21 to 7.99) were separately identified as risk factors for COVID-19 mortality, the patients with both DM and high FIB-4 index had a significantly higher mortality (HR, 9.54; 95% CI, 4.11 to 22.15). Higher FIB-4 indices were associated with higher mortality regardless of DM. A high FIB-4 index with DM was more significantly associated with a severe clinical course with mortality (odds ratio, 11.24; 95% CI, 5.90 to 21.41) than a low FIB-4 index without DM, followed by a high FIB-4 index alone and DM alone. The duration of quarantine and hospital stay also tended to be longer in those with both DM and high FIB-4 index.
Conclusion
Both DM and high FIB-4 index are independent and additive risk factors for COVID-19 mortality.

Citations

Citations to this article as recorded by

COVID-19 and hepatic injury: Diversity and risk assessment
Fares E M Ali, Mostafa K Abd El-Aziz, Mahmoud M Ali, Osama M Ghogar, Adel G Bakr
World Journal of Gastroenterology.2023; 29(3): 425. CrossRef
Differential Effects of COVID-19 Hospitalization on the Trajectory of Liver Disease Progression
Dilara Hatipoğlu, Connor Mulligan, Jeffrey Wang, Juan Peticco, Reid Grinspoon, Sanjay Gadi, Camilla Mills, Jay Luther, Raymond T. Chung
Gastro Hep Advances.2023; 2(4): 480. CrossRef
Association of non-alcoholic fatty liver and metabolic-associated fatty liver with COVID-19 outcomes: A systematic review and meta-analysis
Gowthami Sai Kogilathota Jagirdhar, Rakhtan K Qasba, Harsha Pattnaik, Kaanthi Rama, Akshat Banga, Shiva Teja Reddy, Anna Carolina Flumignan Bucharles, Rahul Kashyap, Praveen Reddy Elmati, Vikas Bansal, Yatinder Bains, Theodore DaCosta, Salim Surani
World Journal of Gastroenterology.2023; 29(21): 3362. CrossRef
COVID-19 and Fatty Liver Disorders
Maria Guarino, Valentina Cossiga, Francesco Cutolo, Maria Attanasio, Raffaele Lieto, Filomena Morisco
Journal of Clinical Medicine.2023; 12(13): 4316. CrossRef
Prevalence and Prognostic Significance of Liver Fibrosis in Patients With Aneurysmal Subarachnoid Hemorrhage
Tiangui Li, Peng Wang, Xiao Gong, Weelic Chong, Yang Hai, Chao You, Juan Kang, Fang Fang, Yu Zhang
Frontiers in Neurology.2022;[Epub] CrossRef

Thyroid
Thyroid Hormone Profile and Its Prognostic Impact on the Coronavirus Disease 2019 in Korean Patients: Jiyeon Ahn, Min Kyung Lee, Jae Hyuk Lee, Seo Young Sohn; Endocrinol Metab. 2021;36(4):769-777. Published online August 27, 2021; DOI: https://doi.org/10.3803/EnM.2021.1109

3,833 View
180 Download
15 Citations

Abstract PDF Supplementary Material PubReader ePub

Background
Data on the association between coronavirus disease 2019 (COVID-19) and thyroid have been reported, including overt thyrotoxicosis and suppression of thyroid function. We aimed to evaluate the thyroid hormone profile and its association with the prognosis of COVID-19 in Korean patients.
Methods
The clinical data of 119 patients with COVID-19, admitted in the Myongji Hospital, Goyang, South Korea, were retrospectively evaluated. The thyroid hormone profiles were analyzed and compared based on disease severity (non-severe disease vs. severe to critical disease). Clinical outcomes were analyzed according to the tertiles of thyroid hormones.
Results
Of the 119 patients, 76 (63.9%) were euthyroid, and none presented with overt thyroid dysfunction. Non-thyroidal illness syndrome was the most common manifestation (18.5%), followed by subclinical thyrotoxicosis (14.3%) among patients with thyroid dysfunction. Thyroid stimulating hormone (TSH) and triiodothyronine (T3) levels were significantly lower in patients with severe to critical disease than in those with non-severe disease (P<0.05). Patients in the lowest T3 tertile (<0.77 ng/mL) had higher rates of mechanical ventilation, intensive care unit admission, and death than those in the middle and highest (>1.00 ng/mL) T3 tertiles (P<0.05). COVID-19 patients in the lowest T3 tertile were independently associated with mortality (hazard ratio, 5.27; 95% confidence interval, 1.09 to 25.32; P=0.038) compared with those in the highest T3 tertile.
Conclusion
Thyroid dysfunction is common in COVID-19 patients. Changes in serum TSH and T3 levels may be important markers of disease severity in COVID-19. Decreased T3 levels may have a prognostic significance in COVID-19 related outcome.

Citations

Citations to this article as recorded by

Thyroxine changes in COVID-19 pandemic: A systematic review and meta-analysis
Ziqi Li, Pengwei Hou, Shuwen Mu, Renzhi Wang, Hui Miao, Ming Feng, He Wang, Wentai Zhang, Yihao Chen, Tianshun Feng, Shousen Wang, Yi Fang
Frontiers in Endocrinology.2023;[Epub] CrossRef
The Influence of SARS-CoV-2 Infection on the Thyroid Gland
Aleksandra Piekarska, Marta Góral, Marta Kozula, Aleksandra Jawiarczyk-Przybyłowska, Katarzyna Zawadzka, Marek Bolanowski
Biomedicines.2023; 11(2): 614. CrossRef
Thyroid Function Abnormalities and Outcomes in Hospitalized Patients with COVID-19 Infection: A Cross-Sectional Study
Deepika Patel, Dukhabandhu Naik, Sadishkumar Kamalanathan, Kadhiravan Tamilarasu, Jayaprakash Sahoo, Ayan Roy, Chandhana Merugu, Varun Suryadevara
Hormone and Metabolic Research.2023; 55(03): 169. CrossRef
The Spectrum of Thyroid Function Tests and Autoantibodies During Hospitalization and After Six Months of Discharge in COVID-19 Patients: Does COVID-19 Trigger Autoimmunity?
Ziynet Alphan Uc, Pinar Yagcı, Zelal Adibelli, Cevdet Duran
Endocrine Research.2023; 48(2-3): 44. CrossRef
Transient low T3 syndrome in patients with COVID-19: a new window for prediction of disease severity
Mingyao Zhong, Yue Gao, Hongling Hu, Xuan Zhu, Lulu Gan, Ling Li, Cheng Xiang, Yimin Yan, Zhe Dai
Frontiers in Endocrinology.2023;[Epub] CrossRef
The Association Between COVID-19 and Thyroxine Levels: A Meta-Analysis
Yiru Chen, Xiuneng Li, Yu Dai, Jingjing Zhang
Frontiers in Endocrinology.2022;[Epub] CrossRef
The New Entity of Subacute Thyroiditis amid the COVID-19 Pandemic: From Infection to Vaccine
Mihaela Popescu, Adina Ghemigian, Corina Maria Vasile, Andrei Costache, Mara Carsote, Alice Elena Ghenea
Diagnostics.2022; 12(4): 960. CrossRef
Potential of Endogenous Oxytocin in Endocrine Treatment and Prevention of COVID-19
Stephani C. Wang, Fengmin Zhang, Hui Zhu, Haipeng Yang, Yang Liu, Ping Wang, Vladimir Parpura, Yu-Feng Wang
Frontiers in Endocrinology.2022;[Epub] CrossRef
The Association Between FT3 With the Outcome and Inflammation/Coagulopathy/Fibrinolysis of COVID-19
Jiayi Deng, Siye Zhang, Fei Peng, Quan Zhang, Yi Li, Yanjun Zhong
Frontiers in Endocrinology.2022;[Epub] CrossRef
Primary hypothyroidism with an episode of ventricular tachycardia in a patient with COVID-19
Pin-Hsu Liao, Yu-Cheng Cheng, Po-Yu Liu, I-Te Lee
Medicine.2022; 101(25): e29243. CrossRef
Low triiodothyronine syndrome is associated with stroke‐associated pneumonia
Huijun Chen, Minjie Xu, Yezhi Huang, Jincai He, Wenwei Ren
European Journal of Clinical Investigation.2022;[Epub] CrossRef
Association of thyroid dysfunction and COVID-19: A systematic review and meta-analysis
Mohammad Darvishi, Mohammad Reza Nazer, Hamze Shahali, Majid Nouri
Frontiers in Endocrinology.2022;[Epub] CrossRef
The prognostic utility of serum thyrotropin in hospitalized Covid-19 patients: statistical and machine learning approaches
E. Pappa, P. Gourna, G. Galatas, M. Manti, A. Romiou, L. Panagiotou, R. Chatzikyriakou, N. Trakas, G. Feretzakis, C. Christopoulos
Endocrine.2022; 80(1): 86. CrossRef
Thyrotropin Levels in Patients with Coronavirus Disease 2019: Assessment during Hospitalization and in the Medium Term after Discharge
Abdallah Al-Salameh, Noémie Scherman, Imane Adda, Juliette André, Yoann Zerbib, Julien Maizel, Jean-Daniel Lalau, Etienne Brochot, Claire Andrejak, Rachel Desailloud
Life.2022; 12(12): 2014. CrossRef
COVID-19 and thyroid function: What do we know so far?
Camila Lüdke Rossetti, Juliana Cazarin, Fabio Hecht, Fabyan Esberard de Lima Beltrão, Andrea Cláudia Freitas Ferreira, Rodrigo Soares Fortunato, Helton Estrela Ramos, Denise Pires de Carvalho
Frontiers in Endocrinology.2022;[Epub] CrossRef

Special Article

Miscellaneous
COVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society: Cheol Ryong Ku, Kyong Yeun Jung, Chang Ho Ahn, Jun Sung Moon, Ju Hee Lee, Eun Heui Kim, Hyemi Kwon, Hee Kyung Kim, Sunghwan Suh, Sangmo Hong, Jeonghoon Ha, Eun Roh, Jin Hwa Kim, Mi-kyung Kim, the Committee of Clinical Practice Guideline of the Korean Endocrine Society; Endocrinol Metab. 2021;36(4):757-765. Published online August 17, 2021; DOI: https://doi.org/10.3803/EnM.2021.404

9,124 View
405 Download
20 Citations

Abstract PDF PubReader ePub

Since the first outbreak of coronavirus disease 2019 (COVID-19), ongoing efforts have been made to discover an efficacious vaccine against COVID-19 to combat the pandemic. In most countries, both mRNA and DNA vaccines have been administered, and their side effects have also been reported. The clinical course of COVID-19 and the effects of vaccination against COVID-19 are both influenced by patients’ health status and involve a systemic physiological response. In view of the systemic function of endocrine hormones, endocrine disorders themselves and the therapeutics used to treat them can influence the outcomes of vaccination for COVID-19. However, there are very limited data to support the development of clinical guidelines for patients with specific medical backgrounds based on large clinical trials. In the current severe circumstances of the COVID-19 pandemic, position statements made by clinical specialists are essential to provide appropriate recommendations based on both medical evidence and clinical experiences. As endocrinologists, we would like to present the medical background of COVID-19 vaccination, as well as precautions to prevent the side effects of COVID-19 vaccination in patients with specific endocrine disorders, including adrenal insufficiency, diabetes mellitus, osteoporosis, autoimmune thyroid disease, hypogonadism, and pituitary disorders.

Citations

Citations to this article as recorded by

Adult-Onset Type 1 Diabetes Development Following COVID-19 mRNA Vaccination
Hyeyeon Moon, Sunghwan Suh, Mi Kyoung Park
Journal of Korean Medical Science.2023;[Epub] CrossRef
Prior immunization status of COVID-19 patients and disease severity: A multicenter retrospective cohort study assessing the different types of immunity
Javaria Aslam, Faisal Shahzad Khan, Muhammad Talha Haris, Hewad Hewadmal, Maryam Khalid, Mohammad Y. Alshahrani, Qurrat-ul-ain Aslam, Irrum Aneela, Urooj Zafar
Vaccine.2023; 41(2): 598. CrossRef
Mortality and Severity of Coronavirus Disease 2019 in Patients with Long-Term Glucocorticoid Therapy: A Korean Nationwide Cohort Study
Eu Jeong Ku, Keeho Song, Kyoung Min Kim, Gi Hyeon Seo, Soon Jib Yoo
Endocrinology and Metabolism.2023; 38(2): 253. CrossRef
Pituitary Diseases and COVID-19 Outcomes in South Korea: A Nationwide Cohort Study
Jeonghoon Ha, Kyoung Min Kim, Dong-Jun Lim, Keeho Song, Gi Hyeon Seo
Journal of Clinical Medicine.2023; 12(14): 4799. CrossRef
Inactivated SARS-CoV-2 vaccination does not disturb the clinical course of Graves’ disease: An observational cohort study
Shichen Xu, Huixin Yu, Xian Cheng, Jing Wu, Jiandong Bao, Li Zhang
Vaccine.2023; 41(38): 5648. CrossRef
Adrenal Crisis Associated With COVID-19 Vaccination in Patients With Adrenal Insufficiency
Yukako Kurematsu, Takako Mohri, Sadanori Okada, Yutaka Takahashi
JCEM Case Reports.2023;[Epub] CrossRef
Adverse Events Associated with COVID-19 Vaccination in Adolescents with Endocrinological Disorders: A Cross-Sectional Study
İbrahim Mert Erbaş, İrem Ceren Erbaş, Gözde Akın Kağızmanlı, Kübra Yüksek Acinikli, Özge Besci, Korcan Demir, Ece Böber, Nurşen Belet, Ayhan Abacı
Journal of Clinical Research in Pediatric Endocrinology.2023; 15(3): 248. CrossRef
The role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands
C. Ouaddouh, J.W. Duijster, T. Lieber, F.P.A.M. van Hunsel
Expert Opinion on Drug Safety.2023; : 1. CrossRef
Neue Aspekte der Glukokortikoidsubstitution bei Nebennierenrindeninsuffizienz
Tina Kienitz, Gesine Meyer
Der Internist.2022; 63(1): 12. CrossRef
Endocrine Follow-up During Post-Acute COVID-19: Practical Recommendations Based on Available Clinical Evidence
Rimesh Pal, Ameya Joshi, Sanjay K. Bhadada, Mainak Banerjee, Suresh Vaikkakara, Satinath Mukhopadhyay
Endocrine Practice.2022; 28(4): 425. CrossRef
Safety of Inactivated and mRNA COVID-19 Vaccination Among Patients Treated for Hypothyroidism: A Population-Based Cohort Study
Xi Xiong, Carlos King Ho Wong, Ivan Chi Ho Au, Francisco Tsz Tsun Lai, Xue Li, Eric Yuk Fai Wan, Celine Sze Ling Chui, Esther Wai Yin Chan, Franco Wing Tak Cheng, Kristy Tsz Kwan Lau, Chi Ho Lee, Yu Cho Woo, David Tak Wai Lui, Ian Chi Kei Wong
Thyroid.2022; 32(5): 505. CrossRef
The New Entity of Subacute Thyroiditis amid the COVID-19 Pandemic: From Infection to Vaccine
Mihaela Popescu, Adina Ghemigian, Corina Maria Vasile, Andrei Costache, Mara Carsote, Alice Elena Ghenea
Diagnostics.2022; 12(4): 960. CrossRef
Adrenal Crisis Secondary to COVID-19 Vaccination in a Patient With Hypopituitarism
Nikolina Markovic, Anila Faizan, Chirag Boradia, Sridhar Nambi
AACE Clinical Case Reports.2022; 8(4): 171. CrossRef
The Effect of Inactivated SARS-CoV-2 Vaccines on TRAB in Graves’ Disease
LingHong Huang, ZhengRong Jiang, JingXiong Zhou, YuPing Chen, HuiBin Huang
Frontiers in Endocrinology.2022;[Epub] CrossRef
Osteoporosis in Patients With Respiratory Diseases
Yue Ma, Shui Qiu, Renyi Zhou
Frontiers in Physiology.2022;[Epub] CrossRef
Pilot Findings on SARS-CoV-2 Vaccine-Induced Pituitary Diseases: A Mini Review from Diagnosis to Pathophysiology
Ach Taieb, El Euch Mounira
Vaccines.2022; 10(12): 2004. CrossRef
Forty Years Together, New Leap Forward! The 40th Anniversary of the Korean Endocrine Society
Jong Chul Won, Ki-Hyun Baek
Endocrinology and Metabolism.2022; 37(6): 851. CrossRef
No need of glucocorticoid dose adjustment in patients with adrenal insufficiency before COVID-19 vaccine
Tania Pilli, Cristina Dalmiglio, Gilda Dalmazio, Alfonso Sagnella, Raffaella Forleo, Lucia Brilli, Fabio Maino, Cristina Ciuoli, Maria Grazia Castagna
European Journal of Endocrinology.2022; 187(1): K7. CrossRef
COVID-19 mRNA vaccine may trigger subacute thyroiditis
Mehmet Sözen, Ömercan Topaloğlu, Berrin Çetinarslan, Alev Selek, Zeynep Cantürk, Emre Gezer, Damla Köksalan, Taner Bayraktaroğlu
Human Vaccines & Immunotherapeutics.2021; 17(12): 5120. CrossRef
Diabetes and COVID-19 Vaccination
Hae Dong Choi, Jun Sung Moon
The Journal of Korean Diabetes.2021; 22(4): 221. CrossRef

Original Articles

Clinical Study
Fasting Plasma Glucose Level Independently Predicts the Mortality of Patients with Coronavirus Disease 2019 Infection: A Multicenter, Retrospective Cohort Study: Min Cheol Chang, Jong-Moon Hwang, Jae-Han Jeon, Sang Gyu Kwak, Donghwi Park, Jun Sung Moon; Endocrinol Metab. 2020;35(3):595-601. Published online August 26, 2020; DOI: https://doi.org/10.3803/EnM.2020.719

6,371 View
180 Download
16 Citations

Abstract PDF Supplementary Material PubReader ePub

Background
Coronavirus disease 2019 (COVID-19) has become a global pandemic, which prompts a consensus for the necessity to seek risk factors for this critical disease. Risk factors affecting mortality of the disease remain elusive. Diabetes and hyperglycemia are known to negatively affect a host’s antiviral immunity. We evaluated the relationship between a history of diabetes, fasting plasma glucose (FPG) levels and mortality among severely ill patients with COVID-19.
Methods
This was a retrospective cohort study that assessed 106 adult inpatients (aged ≥18 years) from two tertiary hospitals in Daegu, South Korea. The participants were transferred to tertiary hospitals because their medical condition required immediate intensive care. The demographic and laboratory data were compared between COVID-19 patients who survived and those who did not.
Results
Compared with the survivor group, age, and the proportions of diabetes, chronic lung disease and FPG were significantly higher in the deceased group. In the Cox proportional hazards regression model for survival analysis, FPG level and age were identified as significant predictors of mortality (P<0.05). The threshold values for predicting high mortality were age >68 years and FPG of 168 mg/dL, respectively. Among those without diabetes, high FPG remained a significant predictor of mortality (P<0.04).
Conclusion
High FPG levels significantly predicted mortality in COVID-19, regardless of a known history of diabetes. These results suggest intensive monitoring should be provided to COVID-19 patients who have a high FPG level.

Citations

Citations to this article as recorded by

Fasting Plasma Glucose Levels at the Time of Admission Predict 90-Day Mortality in Patients with Viral Pneumonia. A Prospective Study
Jie Xu, Jianyu Zhao, Liyuan Wu, Xinxin Lu
Experimental and Clinical Endocrinology & Diabetes.2023; 131(05): 290. CrossRef
Influence of Fasting Plasma Glucose Level on Admission of COVID-19 Patients: A Retrospective Study
Yingying Zhao, Huichun Xing, Yong Xu
Journal of Diabetes Research.2022; 2022: 1. CrossRef
The Role of Diabetes and Hyperglycemia on COVID-19 Infection Course—A Narrative Review
Evangelia Tzeravini, Eleftherios Stratigakos, Chris Siafarikas, Anastasios Tentolouris, Nikolaos Tentolouris
Frontiers in Clinical Diabetes and Healthcare.2022;[Epub] CrossRef
Novel Glycemic Index Based on Continuous Glucose Monitoring to Predict Poor Clinical Outcomes in Critically Ill Patients: A Pilot Study
Eun Yeong Ha, Seung Min Chung, Il Rae Park, Yin Young Lee, Eun Young Choi, Jun Sung Moon
Frontiers in Endocrinology.2022;[Epub] CrossRef
Heterogeneity and Risk of Bias in Studies Examining Risk Factors for Severe Illness and Death in COVID-19: A Systematic Review and Meta-Analysis
Abraham Degarege, Zaeema Naveed, Josiane Kabayundo, David Brett-Major
Pathogens.2022; 11(5): 563. CrossRef
Global, Regional and National Burden of Cancers Attributable to High Fasting Plasma Glucose in 204 Countries and Territories, 1990-2019
Saeid Safiri, Seyed Aria Nejadghaderi, Nahid Karamzad, Jay S. Kaufman, Kristin Carson-Chahhoud, Nicola Luigi Bragazzi, Mark J. M. Sullman, Mohammad Reza Beyranvand, Mohammad Ali Mansournia, Amir Almasi-Hashiani, Gary S. Collins, Ali-Asghar Kolahi
Frontiers in Endocrinology.2022;[Epub] CrossRef
COVID-19 and diabetes—Two giants colliding: From pathophysiology to management
Maria Chiara Pelle, Isabella Zaffina, Michele Provenzano, Giovenale Moirano, Franco Arturi
Frontiers in Endocrinology.2022;[Epub] CrossRef
SARS-CoV-2 omicron variant clearance delayed in breakthrough cases with elevated fasting blood glucose
Xiujun Zhang, Guocan Si, Huifen Lu, Wei Zhang, Shuqin Zheng, Zeyu Huang, Longgen Liu, Yuan Xue, Guojun Zheng
Virology Journal.2022;[Epub] CrossRef
Hyperglycemia is Associated With Increased Mortality in Critically Ill Patients With COVID-19
Alon Y. Mazori, Ilana Ramer Bass, Lili Chan, Kusum S. Mathews, Deena R. Altman, Aparna Saha, Howard Soh, Huei Hsun Wen, Sonali Bose, Emily Leven, Jing Gennie Wang, Gohar Mosoyan, Pattharawin Pattharanitima, Giampaolo Greco, Emily J. Gallagher
Endocrine Practice.2021; 27(2): 95. CrossRef
The common risk factors for progression and mortality in COVID-19 patients: a meta-analysis
Li Zhang, Jie Hou, Fu-Zhe Ma, Jia Li, Shuai Xue, Zhong-Gao Xu
Archives of Virology.2021; 166(8): 2071. CrossRef
Dyslipidaemia and mortality in COVID-19 patients: a meta-analysis
M Zuin, G Rigatelli, C Bilato, C Cervellati, G Zuliani, L Roncon
QJM: An International Journal of Medicine.2021; 114(6): 390. CrossRef
National early warning score on admission as risk factor for invasive mechanical ventilation in COVID-19 patients
Min Cheol Chang, Tae Uk Kim, Donghwi Park
Medicine.2021; 100(19): e25917. CrossRef
Thyroid Hormone Profile and Its Prognostic Impact on the Coronavirus Disease 2019 in Korean Patients
Jiyeon Ahn, Min Kyung Lee, Jae Hyuk Lee, Seo Young Sohn
Endocrinology and Metabolism.2021; 36(4): 769. CrossRef
Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies
Yahya Mahamat-Saleh, Thibault Fiolet, Mathieu Edouard Rebeaud, Matthieu Mulot, Anthony Guihur, Douae El Fatouhi, Nasser Laouali, Nathan Peiffer-Smadja, Dagfinn Aune, Gianluca Severi
BMJ Open.2021; 11(10): e052777. CrossRef
COVID-19 und Diabetes: Folgen der Pandemie
Baptist Gallwitz, Wolfgang Rathmann
Deutsches Ärzteblatt Online.2021;[Epub] CrossRef
Incidence of Post-Traumatic Stress Disorder after Coronavirus Disease
Min Cheol Chang, Donghwi Park
Healthcare.2020; 8(4): 373. CrossRef

Thyroid
Insights from a Prospective Follow-up of Thyroid Function and Autoimmunity among COVID-19 Survivors: David Tak Wai Lui, Chi Ho Lee, Wing Sun Chow, Alan Chun Hong Lee, Anthony Raymond Tam, Carol Ho Yi Fong, Chun Yiu Law, Eunice Ka Hong Leung, Kelvin Kai Wang To, Kathryn Choon Beng Tan, Yu Cho Woo, Ching Wan Lam, Ivan Fan Ngai Hung, Karen Siu Ling Lam; Endocrinol Metab. 2021;36(3):582-589. Published online June 8, 2021; DOI: https://doi.org/10.3803/EnM.2021.983

9,808 View
252 Download
31 Citations

Abstract PDF PubReader ePub

Background
The occurrence of Graves’ disease and Hashimoto thyroiditis after coronavirus disease 2019 (COVID-19) raised concerns that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may trigger thyroid autoimmunity. We aimed to address the current uncertainties regarding incident thyroid dysfunction and autoimmunity among COVID-19 survivors.
Methods
We included consecutive adult COVID-19 patients without known thyroid disorders, who were admitted to Queen Mary Hospital from July 21 to September 21, 2020 and had serum levels of thyroid-stimulating hormone, free thyroxine, free triiodothyronine (fT3), and anti-thyroid antibodies measured both on admission and at 3 months.
Results
In total, 122 patients were included. Among 20 patients with abnormal thyroid function tests (TFTs) on admission (mostly low fT3), 15 recovered. Among 102 patients with initial normal TFTs, two had new-onset abnormalities that could represent different phases of thyroiditis. Among 104 patients whose anti-thyroid antibody titers were reassessed, we observed increases in anti-thyroid peroxidase (TPO) (P<0.001) and anti-thyroglobulin (P<0.001), but not anti-thyroid stimulating hormone receptor titers (P=0.486). Of 82 patients with negative anti-TPO findings at baseline, 16 had a significant interval increase in anti-TPO titer by >12 U, and four became anti-TPO-positive. Worse baseline clinical severity (P=0.018), elevated C-reactive protein during hospitalization (P=0.033), and higher baseline anti-TPO titer (P=0.005) were associated with a significant increase in anti-TPO titer.
Conclusion
Most patients with thyroid dysfunction on admission recovered during convalescence. Abnormal TFTs suggestive of thyroiditis occurred during convalescence, but infrequently. Importantly, our novel observation of an increase in anti-thyroid antibody titers post-COVID-19 warrants further follow-up for incident thyroid dysfunction among COVID-19 survivors.

Citations

Citations to this article as recorded by

The most common persistent symptoms in patients with COVID-19 who were evaluated in the Internal Medicine polyclinic
Zeynep KOÇ, Seydahmet AKIN
The European Research Journal.2023; 9(1): 97. CrossRef
Clinical assessment of children with long COVID syndrome
Réka Garai, Péter Krivácsy, Vivien Herczeg, Fanni Kovács, Bálint Tél, Judit Kelemen, Anna Máthé, Eszter Zsáry, Johanna Takács, Dániel Sándor Veres, Attila J. Szabó
Pediatric Research.2023; 93(6): 1616. CrossRef
T Cell Receptor Sequences Amplified during Severe COVID-19 and Multisystem Inflammatory Syndrome in Children Mimic SARS-CoV-2, Its Bacterial Co-Infections and Host Autoantigens
Robert Root-Bernstein, Elizabeth Churchill, Shelby Oliverio
International Journal of Molecular Sciences.2023; 24(2): 1335. CrossRef
A Literature Review on SARS-CoV-2 and Other Viruses in Thyroid Disorders: Environmental Triggers or No-Guilty Bystanders?
Francesca Gorini, Cristina Vassalle
International Journal of Environmental Research and Public Health.2023; 20(3): 2389. CrossRef
Thyroid dysfunction as a long-term post-COVID-19 complication in mild-to-moderate COVID-19
Vesselina Yanachkova, Teodora Stankova, Radiana Staynova
Biotechnology & Biotechnological Equipment.2023; 37(1): 194. CrossRef
The Influence of SARS-CoV-2 Infection on the Thyroid Gland
Aleksandra Piekarska, Marta Góral, Marta Kozula, Aleksandra Jawiarczyk-Przybyłowska, Katarzyna Zawadzka, Marek Bolanowski
Biomedicines.2023; 11(2): 614. CrossRef
Thyroid Function Abnormalities and Outcomes in Hospitalized Patients with COVID-19 Infection: A Cross-Sectional Study
Deepika Patel, Dukhabandhu Naik, Sadishkumar Kamalanathan, Kadhiravan Tamilarasu, Jayaprakash Sahoo, Ayan Roy, Chandhana Merugu, Varun Suryadevara
Hormone and Metabolic Research.2023; 55(03): 169. CrossRef
The Spectrum of Thyroid Function Tests and Autoantibodies During Hospitalization and After Six Months of Discharge in COVID-19 Patients: Does COVID-19 Trigger Autoimmunity?
Ziynet Alphan Uc, Pinar Yagcı, Zelal Adibelli, Cevdet Duran
Endocrine Research.2023; 48(2-3): 44. CrossRef
Increased prevalence of autoimmune thyroid disease after COVID-19: A single-center, prospective study
Alessandro Rossini, Sara Cassibba, Francesca Perticone, Simone Vasilij Benatti, Serena Venturelli, Greta Carioli, Arianna Ghirardi, Marco Rizzi, Tiziano Barbui, Roberto Trevisan, Silvia Ippolito
Frontiers in Endocrinology.2023;[Epub] CrossRef
A prospective follow-up of thyroid volume and thyroiditis features on ultrasonography among survivors of predominantly mild to moderate COVID-19
Man Him Matrix Fung, David Tak Wai Lui, Keith Wan Hang Chiu, Sherman Haynam Lee, Chi Ho Lee, Wing Sun Chow, Alan Chun Hong Lee, Anthony Raymond Tam, Polly Pang, Tip Yin Ho, Carol Ho Yi Fong, Connie Hong Nin Loong, Chun Yiu Law, Kelvin Kai Wang To, Ching W
PeerJ.2023; 11: e15034. CrossRef
Study on Clinicopathological Features and Risk Factors of Patients with Multiple Primary Breast Cancers and Thyroid Disease
Jie Li, Yonghong Liu, Jian Jin, Qingfeng Shi, Yanting Ji, Bo Zhang, Pengfei Hu, Jinghua Pan
Mediators of Inflammation.2023; 2023: 1. CrossRef
Beyond Acute COVID-19: Investigating the Incidence of Subacute Thyroiditis in Long COVID-19 in Korea
Jeongmin Lee, Gi Hyeon Seo, Keeho Song
Endocrinology and Metabolism.2023; 38(4): 455. CrossRef
Thyroid Autoimmunity and SARS-CoV-2 Infection
Poupak Fallahi, Giusy Elia, Francesca Ragusa, Sabrina Rosaria Paparo, Armando Patrizio, Eugenia Balestri, Valeria Mazzi, Salvatore Benvenga, Gilda Varricchi, Laura Gragnani, Chiara Botrini, Enke Baldini, Marco Centanni, Clodoveo Ferri, Alessandro Antonell
Journal of Clinical Medicine.2023; 12(19): 6365. CrossRef
Autoimmune complications of COVID‐19
Niloufar Yazdanpanah, Nima Rezaei
Journal of Medical Virology.2022; 94(1): 54. CrossRef
The Independent Association of TSH and Free Triiodothyronine Levels With Lymphocyte Counts Among COVID-19 Patients
David Tak Wai Lui, Chi Ho Lee, Wing Sun Chow, Alan Chun Hong Lee, Anthony Raymond Tam, Polly Pang, Tip Yin Ho, Chloe Yu Yan Cheung, Carol Ho Yi Fong, Chun Yiu Law, Kelvin Kai Wang To, Ching Wan Lam, Kathryn Choon Beng Tan, Yu Cho Woo, Ivan Fan Ngai Hung,
Frontiers in Endocrinology.2022;[Epub] CrossRef
Comment on Khunti et al. COVID-19, Hyperglycemia, and New-Onset Diabetes. Diabetes Care 2021;44:2645–2655
Carmine Gazzaruso, Adriana Coppola, Pietro Gallotti, Ileana Terruzzi, Tiziana Montalcini, Livio Luzi
Diabetes Care.2022; 45(2): e45. CrossRef
The potential impact of COVID-19 on thyroid gland volumes among COVID-19 survivors
Emre Urhan, Zuleyha Karaca, Canan Sehit Kara, Zeynep Ture Yuce, Kursad Unluhizarci
Endocrine.2022; 76(3): 635. CrossRef
Systematic review of COVID-19 and autoimmune thyroiditis
Esra Tutal, Resat Ozaras, Hakan Leblebicioglu
Travel Medicine and Infectious Disease.2022; 47: 102314. CrossRef
The New Entity of Subacute Thyroiditis amid the COVID-19 Pandemic: From Infection to Vaccine
Mihaela Popescu, Adina Ghemigian, Corina Maria Vasile, Andrei Costache, Mara Carsote, Alice Elena Ghenea
Diagnostics.2022; 12(4): 960. CrossRef
Should we expect a wave of type 1 diabetes following SARS‐CoV‐2 pandemic?
Laura Montefusco, Andrea Mario Bolla, Paolo Fiorina
Diabetes/Metabolism Research and Reviews.2022;[Epub] CrossRef
COVID-19 and Thyroid Function: A Bi-Directional Two-Sample Mendelian Randomization Study
Gloria Hoi-Yee Li, Ching-Man Tang, Ching-Lung Cheung
Thyroid.2022; 32(9): 1037. CrossRef
Development of a prediction score (ThyroCOVID) for identifying abnormal thyroid function in COVID-19 patients
D. T. W. Lui, C. H. Lee, W. S. Chow, A. C. H. Lee, A. R. Tam, C. Y. Y. Cheung, C. H. Y. Fong, S. T. M. Kwok, C. Y. Law, K. K. W. To, C. W. Lam, K. C. B. Tan, Y. C. Woo, I. F. N. Hung, K. S. L. Lam
Journal of Endocrinological Investigation.2022; 45(11): 2149. CrossRef
Symptomatic Bradycardia Manifesting as Acute Hypothyroidism Following COVID-19 Infection: A Case Report
Jaydip Desai, Arsh N Patel, Courtney L Evans, Molly Triggs, Fulton Defour
Cureus.2022;[Epub] CrossRef
Schilddrüse und SARS-CoV-2
Georg Zettinig
Journal für Klinische Endokrinologie und Stoffwechsel.2022; 15(3): 100. CrossRef
Thyroid diseases are associated with coronavirus disease 2019 infection
Yutian Tian, Junyu Zhao, Tingting Wang, Haipeng Wang, Jinming Yao, Song Wang, Yaru Mou
Frontiers in Endocrinology.2022;[Epub] CrossRef
Thyrotropin Levels in Patients with Coronavirus Disease 2019: Assessment during Hospitalization and in the Medium Term after Discharge
Abdallah Al-Salameh, Noémie Scherman, Imane Adda, Juliette André, Yoann Zerbib, Julien Maizel, Jean-Daniel Lalau, Etienne Brochot, Claire Andrejak, Rachel Desailloud
Life.2022; 12(12): 2014. CrossRef
Long COVID in Patients With Mild to Moderate Disease: Do Thyroid Function and Autoimmunity Play a Role?
David Tak Wai Lui, Chi Ho Lee, Wing Sun Chow, Alan Chun Hong Lee, Anthony Raymond Tam, Polly Pang, Tip Yin Ho, Carol Ho Yi Fong, Chun Yiu Law, Eunice Ka Hong Leung, Kelvin Kai Wang To, Kathryn Choon Beng Tan, Yu Cho Woo, Ching Wan Lam, Ivan Fan Ngai Hung,
Endocrine Practice.2021; 27(9): 894. CrossRef
Hashimoto’s thyroiditis following SARS-CoV-2 infection
Rafael Silvestre Knack, Taliê Hanada, Renata Silvestre Knack, Kamilla Mayr
BMJ Case Reports.2021; 14(8): e244909. CrossRef
Higher SARS-CoV-2 viral loads correlated with smaller thyroid volumes on ultrasound among male COVID-19 survivors
David Tak Wai Lui, Matrix Man Him Fung, Keith Wan Hang Chiu, Chi Ho Lee, Wing Sun Chow, Alan Chun Hong Lee, Anthony Raymond Tam, Polly Pang, Tip Yin Ho, Carol Ho Yi Fong, Connie Hong Nin Loong, Wade Wei Wong, Cassandra Yuen Yan Lee, Chun Yiu Law, Kelvin K
Endocrine.2021; 74(2): 205. CrossRef
SARS-CoV-2: Emerging Role in the Pathogenesis of Various Thyroid Diseases
Avaniyapuram Kannan Murugan, Ali S Alzahrani
Journal of Inflammation Research.2021; Volume 14: 6191. CrossRef
POST-COVID ENDOCRINOPATHY :ABOUT A CASE ENDOCRINOPATHIE POST- COVID :À PROPOS D’UN CAS
S. Rafi, G. Elmghari, N, Elansari
INDIAN JOURNAL OF APPLIED RESEARCH.2021; : 13. CrossRef

Thyroid
Beyond Acute COVID-19: Investigating the Incidence of Subacute Thyroiditis in Long COVID-19 in Korea: Jeongmin Lee, Gi Hyeon Seo, Keeho Song; Endocrinol Metab. 2023;38(4):455-461. Published online August 8, 2023; DOI: https://doi.org/10.3803/EnM.2023.1711

1,743 View
157 Download

Abstract PDF PubReader ePub: Background
The correlation between acute coronavirus disease 2019 (COVID-19) and subacute thyroiditis (SAT) has not been clearly investigated in “long COVID” patients. We aimed to investigate the incidence of SAT during convalescence and after the acute phase of COVID-19, comparing with that of the general population.
Methods
Data from a total of 422,779 COVID-19 patients and a control group of 2,113,895 individuals were analyzed. The index date was defined as the date 3 months after confirmation of COVID-19. The incidence rate (IR) of SAT and hazard ratios (HRs) were calculated per 100,000 persons. Subgroup analysis included analysis of HRs 90–179 and 180 days post-COVID-19 diagnosis; and additional analysis was conducted according to hospitalization status, sex, and age group.
Results
The IR of SAT was 17.28 per 100,000 persons (95% confidence interval [CI], 12.56 to 23.20) in the COVID-19 group and 8.63 (95% CI, 6.37 to 11.45) in the control group. The HR of COVID-19 patients was 1.76 (95% CI, 1.01 to 3.06; P=0.045). The HR of SAT was 1.39 (95% CI, 0.82 to 2.34; P=0.220) up to 6 months after the index date and 2.30 (95% CI, 1.60 to 3.30; P<0.001) beyond 6 months. The HR for SAT among COVID-19 patients was 2.00 (95% CI, 1.41 to 2.83) in hospitalized patients and 1.76 (95% CI, 1.01 to 3.06) in non-hospitalized patients compared to the control group. The IR of SAT was 27.09 (95% CI, 20.04 to 35.82) for females and 6.47 (95% CI, 3.34 to 11.30) for males. In the 19 to 64 age group, the IR of SAT was 18.19 (95% CI, 13.70 to 23.67), while the IR was 9.18 (95% CI, 7.72 to 10.84) in the 65 to 69 age group.
Conclusion
SAT could be a potential long-term complication of COVID-19. Long-term surveillance for thyroid dysfunction is needed especially in hospitalized, female and young-aged subjects.

Review Articles

Calcium & Bone Metabolism
Interplay of Vitamin D and CYP3A4 Polymorphisms in Endocrine Disorders and Cancer: Siva Swapna Kasarla, Vannuruswamy Garikapati, Yashwant Kumar, Sujatha Dodoala; Endocrinol Metab. 2022;37(3):392-407. Published online June 3, 2022; DOI: https://doi.org/10.3803/EnM.2021.1349

4,243 View
183 Download
4 Citations

Abstract PDF PubReader ePub

Vitamin D has received considerable optimistic attention as a potentially important factor in many pathological states over the past few decades. However, the proportion of the active form of vitamin D metabolites responsible for biological activity is highly questionable in disease states due to flexible alterations in the enzymes responsible for their metabolism. For instance, CYP3A4 plays a crucial role in the biotransformation of vitamin D and other drug substances. Food-drug and/or drug-drug interactions, the disease state, genetic polymorphism, age, sex, diet, and environmental factors all influence CYP3A4 activity. Genetic polymorphisms in CYP450-encoding genes have received considerable attention in the past few decades due to their extensive impact on the pharmacokinetic and dynamic properties of drugs and endogenous substances. In this review, we focused on CYP3A4 polymorphisms and their interplay with vitamin D metabolism and summarized the role of vitamin D in calcium homeostasis, bone diseases, diabetes, cancer, other diseases, and drug substances. We also reviewed clinical observations pertaining to CYP3A4 polymorphisms among the aforementioned disease conditions. In addition, we highlighted the future perspectives of studying the pharmacogenetics of CYP3A4, which may have potential clinical significance for developing novel diagnostic genetic markers that will ascertain disease risk and progression.

Citations

Citations to this article as recorded by

Heat stress as a potential risk factor for vitamin D deficiency
Martina Balducci, Letizia Pruccoli, Andrea Tarozzi
Medical Hypotheses.2023; 176: 111085. CrossRef
Association and Haplotype Analysis of the PON1, ITGB3 and CYP3A4 Genes, Strong Candidates for Familial Coronary Artery Disease Susceptibility
Faruk SAYDAM, İrfan DEĞİRMENCİ, Alparslan BİRDANE, Cansu ÖZBAYER, Taner ULUS, Mahmut ÖZDEMİR, Necmi ATA, Hasan Veysi GÜNEŞ
Online Türk Sağlık Bilimleri Dergisi.2023; 8(1): 81. CrossRef
Association of flame retardants, polybrominated diethyl ethers (PBDEs), with vitamin D in female subjects
Alexandra E. Butler, Edwina Brennan, Daniel S. Drage, Thozhukat Sathyapalan, Stephen L. Atkin
Chemosphere.2023; 338: 139488. CrossRef
Genetic variations of CYP3A4 on the metabolism of itraconazole in vitro
Sai-li Xie, Xiayan Zhu, Nanyong Gao, Qianmeng Lin, Chaojie Chen, Yun-jun Yang, Jian-ping Cai, Guo-xin Hu, Ren-ai Xu
Food and Chemical Toxicology.2023; 181: 114101. CrossRef

Thyroid
Best Achievements in Clinical Thyroidology in 2020: Eun Kyung Lee, Young Joo Park; Endocrinol Metab. 2021;36(1):30-35. Published online February 24, 2021; DOI: https://doi.org/10.3803/EnM.2021.103

3,888 View
239 Download
3 Citations

Abstract PDF PubReader ePub

This review highlights the most interesting research in thyroidology conducted in 2020. The publications of interest discussed below dealt with the following topics: thyroid dysfunction, risk of thyroid cancer, molecular diagnostics and new therapeutics for thyroid cancer, and thyroid disease in the coronavirus disease 2019 pandemic era.

Citations

Citations to this article as recorded by

Compensation for iodine deficiency conditions with drugs based on duckweed substrate
M. Kh. Sadulaev, M. I. Usmanova, T. T. Tataev, A. M. Inderbiev, A. S.-A. Zhamalullayla, A. Salamova
BIO Web of Conferences.2023; 76: 03002. CrossRef
Use of long non-coding RNAs for the molecular diagnosis of papillary thyroid cancer
Daham Kim, Juyeon Yu, Jiwon Kim, Yoon-a Hwang, Jin Kyong Kim, Cheol Ryong Ku, Jung Hyun Yoon, Jin Young Kwak, Kee-Hyun Nam, Eun Jig Lee
Frontiers in Oncology.2022;[Epub] CrossRef
Ultrasound-Guided Fine-Needle Aspiration with or without Negative Pressure for Different Types of Thyroid Nodules
Qi Zhou, Wenjun Wu, Fang Wang, Xiaohua Gong, Xiaojun Chen
International Journal of General Medicine.2021; Volume 14: 5475. CrossRef

Original Articles

Adrenal gland Big Data Articles (National Health Insurance Service Database)
Mortality and Severity of Coronavirus Disease 2019 in Patients with Long-Term Glucocorticoid Therapy: A Korean Nationwide Cohort Study: Eu Jeong Ku, Keeho Song, Kyoung Min Kim, Gi Hyeon Seo, Soon Jib Yoo; Endocrinol Metab. 2023;38(2):253-259. Published online March 21, 2023; DOI: https://doi.org/10.3803/EnM.2022.1607

1,853 View
90 Download
2 Citations

Abstract PDF PubReader ePub

Background
The severity of coronavirus disease 2019 (COVID-19) among patients with long-term glucocorticoid treatment (LTGT) has not been established. We aimed to evaluate the association between LTGT and COVID-19 prognosis.
Methods
A Korean nationwide cohort database of COVID-19 patients between January 2019 and September 2021 was used. LTGT was defined as exposure to at least 150 mg of prednisolone (≥5 mg/day and ≥30 days) or equivalent glucocorticoids 180 days before COVID-19 infection. The outcome measurements were mortality, hospitalization, intensive care unit (ICU) admission, length of stay, and mechanical ventilation.
Results
Among confirmed patients with COVID-19, the LTGT group (n=12,794) was older and had a higher proportion of comorbidities than the control (n=359,013). The LTGT group showed higher in-hospital, 30-day, and 90-day mortality rates than the control (14.0% vs. 2.3%, 5.9% vs. 1.1%, and 9.9% vs. 1.8%, respectively; all P<0.001). Except for the hospitalization rate, the length of stay, ICU admission, and mechanical ventilation proportions were significantly higher in the LTGT group than in the control (all P<0.001). Overall mortality was higher in the LTGT group than in the control group, and the significance remained in the fully adjusted model (odds ratio [OR], 5.75; 95% confidence interval [CI], 5.31 to 6.23) (adjusted OR, 1.82; 95% CI, 1.67 to 2.00). The LTGT group showed a higher mortality rate than the control within the same comorbidity score category.
Conclusion
Long-term exposure to glucocorticoids increased the mortality and severity of COVID-19. Prevention and early proactive measures are inevitable in the high-risk LTGT group with many comorbidities.

Citations

Citations to this article as recorded by

Glucocorticoids as a Double-Edged Sword in the Treatment of COVID-19: Mortality and Severity of COVID-19 in Patients Receiving Long-Term Glucocorticoid Therapy
Eun-Hee Cho
Endocrinology and Metabolism.2023; 38(2): 223. CrossRef
Pituitary Diseases and COVID-19 Outcomes in South Korea: A Nationwide Cohort Study
Jeonghoon Ha, Kyoung Min Kim, Dong-Jun Lim, Keeho Song, Gi Hyeon Seo
Journal of Clinical Medicine.2023; 12(14): 4799. CrossRef

Diabetes, obesity and metabolism Big Data Articles (National Health Insurance Service Database)
Risk for Newly Diagnosed Type 2 Diabetes Mellitus after COVID-19 among Korean Adults: A Nationwide Matched Cohort Study: Jong Han Choi, Kyoung Min Kim, Keeho Song, Gi Hyeon Seo; Endocrinol Metab. 2023;38(2):245-252. Published online April 5, 2023; DOI: https://doi.org/10.3803/EnM.2023.1662

1,346 View
99 Download
2 Citations

Abstract PDF PubReader ePub

Background
Coronavirus disease 2019 (COVID-19) can cause various extrapulmonary sequelae, including diabetes. However, it is unclear whether these effects persist 30 days after diagnosis. Hence, we investigated the incidence of newly diagnosed type 2 diabetes mellitus (T2DM) in the post-acute phase of COVID-19.
Methods
This cohort study used data from the Health Insurance Review and Assessment Service, a representative national healthcare database in Korea. We established a cohort of 348,180 individuals diagnosed with COVID-19 without a history of diabetes between January 2020 and September 2021. The control group consisted of sex- and age-matched individuals with neither a history of diabetes nor COVID-19. We assessed the hazard ratios (HR) of newly diagnosed T2DM patients with COVID-19 compared to controls, adjusted for age, sex, and the presence of hypertension and dyslipidemia.
Results
In the post-acute phase, patients with COVID-19 had an increased risk of newly diagnosed T2DM compared to those without COVID-19 (adjusted HR, 1.30; 95% confidence interval [CI], 1.27 to 1.33). The adjusted HRs of non-hospitalized, hospitalized, and intensive care unit-admitted patients were 1.14 (95% CI, 1.08 to 1.19), 1.34 (95% CI, 1.30 to 1.38), and 1.78 (95% CI, 1.59 to 1.99), respectively. The risk of T2DM in patients who were not administered glucocorticoids also increased (adjusted HR, 1.29; 95% CI, 1.25 to 1.32).
Conclusion
COVID-19 may increase the risk of developing T2DM beyond the acute period. The higher the severity of COVID-19 in the acute phase, the higher the risk of newly diagnosed T2DM. Therefore, T2DM should be included as a component of managing long-term COVID-19.

Citations

Citations to this article as recorded by

Pituitary Diseases and COVID-19 Outcomes in South Korea: A Nationwide Cohort Study
Jeonghoon Ha, Kyoung Min Kim, Dong-Jun Lim, Keeho Song, Gi Hyeon Seo
Journal of Clinical Medicine.2023; 12(14): 4799. CrossRef
New-Onset Diabetes Mellitus in COVID-19: A Scoping Review
Anca Pantea Stoian, Ioana-Cristina Bica, Teodor Salmen, Wael Al Mahmeed, Khalid Al-Rasadi, Kamila Al-Alawi, Maciej Banach, Yajnavalka Banerjee, Antonio Ceriello, Mustafa Cesur, Francesco Cosentino, Alberto Firenze, Massimo Galia, Su-Yen Goh, Andrej Janez,
Diabetes Therapy.2023;[Epub] CrossRef

Review Article

Diabetes
Continuous Glucose Monitoring in the Hospital: M. Citlalli Perez-Guzman, Trisha Shang, Jennifer Y. Zhang, Donna Jornsay, David C. Klonoff; Endocrinol Metab. 2021;36(2):240-255. Published online March 31, 2021; DOI: https://doi.org/10.3803/EnM.2021.201

14,730 View
621 Download
20 Citations

Abstract PDF PubReader ePub

Continuous glucose monitors (CGMs) have suddenly become part of routine care in many hospitals. The coronavirus disease 2019 (COVID-19) pandemic has necessitated the use of new technologies and new processes to care for hospitalized patients, including diabetes patients. The use of CGMs to automatically and remotely supplement or replace assisted monitoring of blood glucose by bedside nurses can decrease: the amount of necessary nursing exposure to COVID-19 patients with diabetes; the amount of time required for obtaining blood glucose measurements, and the amount of personal protective equipment necessary for interacting with patients during the blood glucose testing. The United States Food and Drug Administration (FDA) is now exercising enforcement discretion and not objecting to certain factory-calibrated CGMs being used in a hospital setting, both to facilitate patient care and to obtain performance data that can be used for future regulatory submissions. CGMs can be used in the hospital to decrease the frequency of fingerstick point of care capillary blood glucose testing, decrease hyperglycemic episodes, and decrease hypoglycemic episodes. Most of the research on CGMs in the hospital has focused on their accuracy and only recently outcomes data has been reported. A hospital CGM program requires cooperation of physicians, bedside nurses, diabetes educators, and hospital administrators to appropriately select and manage patients. Processes for collecting, reviewing, storing, and responding to CGM data must be established for such a program to be successful. CGM technology is advancing and we expect that CGMs will be increasingly used in the hospital for patients with diabetes.

Citations

Citations to this article as recorded by

The Need for Data Standards and Implementation Policies to Integrate CGM Data into the Electronic Health Record
Juan Espinoza, Nicole Y. Xu, Kevin T. Nguyen, David C. Klonoff
Journal of Diabetes Science and Technology.2023; 17(2): 495. CrossRef
Staff knowledge, attitudes and practices regarding glycaemic management in adult intensive care units: A national survey
Miao Huang, Ruiqi Yang, Chuanlai Zhang, Xiuni Gan
Nursing in Critical Care.2023; 28(6): 931. CrossRef
Continuous Glucose Monitoring for Patients with COVID-19 Pneumonia: Initial Experience at a Tertiary Care Center
Adrian G. Dumitrascu, Michelle F. Perry, Rebecca J. Boone, Maria P. Guzman, Razvan M. Chirila, Allyson W. McNally, Dorin T. Colibaseanu, Shon E. Meek, Colleen T. Ball, Launia J. White, Ana-Maria Chindris
Endocrine Practice.2023; 29(3): 155. CrossRef
Use of Continuous Glucose Monitors to Manage Type 1 Diabetes Mellitus: Progress, Challenges, and Recommendations
Jared G Friedman, Zulma Cardona Matos, Emily D Szmuilowicz, Grazia Aleppo
Pharmacogenomics and Personalized Medicine.2023; Volume 16: 263. CrossRef
Type 1 Diabetes Overview and Perioperative Management
Grace B. Nelson, Kathryn M. Sumpter
Orthopedic Clinics of North America.2023; 54(3): 287. CrossRef
Real-Time Continuous Glucose Monitoring in the Hospital: A Real-World Experience
Samantha R. Spierling Bagsic, Addie L. Fortmann, Rebekah Belasco, Alessandra Bastian, Suzanne Lohnes, Anna Ritko, Haley Sandoval, Mariya Chichmarenko, Emily C. Soriano, Laura Talavera, Athena Philis-Tsimikas
Journal of Diabetes Science and Technology.2023; 17(3): 656. CrossRef
Implementation of Continuous Glucose Monitoring in Critical Care: A Scoping Review
Eileen R. Faulds, Kathleen M. Dungan, Molly McNett
Current Diabetes Reports.2023; 23(6): 69. CrossRef
Clinical Use of Continuous Glucose Monitoring in Critically Ill Pediatric Patients with Diabetic Ketoacidosis
Esther Park, Minsun Kim
Diabetes Technology & Therapeutics.2023; 25(8): 529. CrossRef
Comparison of Glycemia Risk Index with Time in Range for Assessing Glycemic Quality
Ji Yoon Kim, Jee Hee Yoo, Jae Hyeon Kim
Diabetes Technology & Therapeutics.2023; 25(12): 883. CrossRef
A randomized trial of continuous glucose monitoring to improve post‐transplant glycemic control
Nicholas Jandovitz, Sam J. George, Mersema Abate, Adam M. Kressel, Alexandra C. Bolognese, Lawrence Lau, Vinay Nair, Elliot Grodstein
Clinical Transplantation.2023;[Epub] CrossRef
More Green, Less Red: How Color Standardization May Facilitate Effective Use of CGM Data
Richard M. Bergenstal, Gregg D. Simonson, Lutz Heinemann
Journal of Diabetes Science and Technology.2022; 16(1): 3. CrossRef
Continuous glucose monitoring in the hospital: an update in the era of COVID-19
Chikara Gothong, Lakshmi G. Singh, Medha Satyarengga, Elias K. Spanakis
Current Opinion in Endocrinology, Diabetes & Obesity.2022; 29(1): 1. CrossRef
Breakthrough technology for in-hospital glucose monitoring
David Kerr, David Klonoff
The Lancet Diabetes & Endocrinology.2022; 10(5): 304. CrossRef
The Role of the Diabetes Care and Education Specialist in the Hospital Setting

The Science of Diabetes Self-Management and Care.2022; 48(3): 184. CrossRef
Real-Time Monitoring of Blood Parameters in the Intensive Care Unit: State-of-the-Art and Perspectives
Rebecca Bockholt, Shaleen Paschke, Lars Heubner, Bergoi Ibarlucea, Alexander Laupp, Željko Janićijević, Stephanie Klinghammer, Sascha Balakin, Manfred F. Maitz, Carsten Werner, Gianaurelio Cuniberti, Larysa Baraban, Peter Markus Spieth
Journal of Clinical Medicine.2022; 11(9): 2408. CrossRef
Novel Glycemic Index Based on Continuous Glucose Monitoring to Predict Poor Clinical Outcomes in Critically Ill Patients: A Pilot Study
Eun Yeong Ha, Seung Min Chung, Il Rae Park, Yin Young Lee, Eun Young Choi, Jun Sung Moon
Frontiers in Endocrinology.2022;[Epub] CrossRef
Stress-Induced Hyperglycemia: Consequences and Management
Deepanjali Vedantam, Devyani S Poman, Lakshya Motwani, Nailah Asif, Apurva Patel, Krishna Kishore Anne
Cureus.2022;[Epub] CrossRef
Hospital Diabetes Meeting 2022
Jingtong Huang, Andrea M. Yeung, Kevin T. Nguyen, Nicole Y. Xu, Jean-Charles Preiser, Robert J. Rushakoff, Jane Jeffrie Seley, Guillermo E. Umpierrez, Amisha Wallia, Andjela T. Drincic, Roma Gianchandani, M. Cecilia Lansang, Umesh Masharani, Nestoras Math
Journal of Diabetes Science and Technology.2022; 16(5): 1309. CrossRef
Effects of Patient-Driven Lifestyle Modification Using Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: Results From the Randomized Open-label PDF Study
Hun Jee Choe, Eun-Jung Rhee, Jong Chul Won, Kyong Soo Park, Won-Young Lee, Young Min Cho
Diabetes Care.2022; 45(10): 2224. CrossRef
The Devil Is in the Details: Use, Limitations, and Implementation of Continuous Glucose Monitoring in the Inpatient Setting
Rebecca Rick Longo, Renu Joshi
Diabetes Spectrum.2022; 35(4): 405. CrossRef

Editorial

Adrenal gland
Glucocorticoids as a Double-Edged Sword in the Treatment of COVID-19: Mortality and Severity of COVID-19 in Patients Receiving Long-Term Glucocorticoid Therapy: Eun-Hee Cho; Endocrinol Metab. 2023;38(2):223-225. Published online April 27, 2023; DOI: https://doi.org/10.3803/EnM.2023.201

866 View
56 Download

PDF PubReader ePub

Review Article

Miscellaneous
Encountering COVID-19 as Endocrinologists: Eun-Jung Rhee, Jung Hee Kim, Sun Joon Moon, Won-Young Lee; Endocrinol Metab. 2020;35(2):197-205. Published online June 23, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.2.197

12,384 View
269 Download
15 Citations

Abstract PDF PubReader ePub

The world is entering an era of disaster and chaos due to coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2. Since its first emergence in December 2019 in Wuhan, China, COVID-19 has swept through Asia and propagated throughout the world to Europe and North America. As of April 13, 1,773,084 people were infected and 111,652 people had died from COVID-19 globally, and new record levels of infection are being reported every day. Based on the data that have been amassed so far, the primary risk factors for a severe disease course or even mortality from COVID-19 are underlying diseases such as diabetes and hypertension. As the global prevalence of diabetes continues to increase, patients with endocrine diseases such as diabetes mellitus and those who are on long-term corticosteroid therapy due to adrenal insufficiency or hypopituitarism are at risk for a poor prognosis of COVID-19. As endocrinologists, we would like to briefly review the current knowledge about the relationship between COVID-19 and endocrine diseases and to discuss what we can do for the safety and health of our patients with endocrine diseases in this globally threatening situation.

Citations

Citations to this article as recorded by

Adverse Events Associated with COVID-19 Vaccination in Adolescents with Endocrinological Disorders: A Cross-Sectional Study
İbrahim Mert Erbaş, İrem Ceren Erbaş, Gözde Akın Kağızmanlı, Kübra Yüksek Acinikli, Özge Besci, Korcan Demir, Ece Böber, Nurşen Belet, Ayhan Abacı
Journal of Clinical Research in Pediatric Endocrinology.2023; 15(3): 248. CrossRef
Pituitary Diseases and COVID-19 Outcomes in South Korea: A Nationwide Cohort Study
Jeonghoon Ha, Kyoung Min Kim, Dong-Jun Lim, Keeho Song, Gi Hyeon Seo
Journal of Clinical Medicine.2023; 12(14): 4799. CrossRef
New-onset and relapsed Graves’ disease following COVID-19 vaccination: a comprehensive review of reported cases
Kan Chen, Yiyang Gao, Jing Li
European Journal of Medical Research.2023;[Epub] CrossRef
Assessment of Neuroendocrine Changes and Hypothalamo-Pituitary Autoimmunity in Patients with COVID-19
Mustafa Sait Gonen, Annamaria De Bellis, Emre Durcan, Giuseppe Bellastella, Paolo Cirillo, Lorenzo Scappaticcio, Miriam Longo, Basak Ecem Bircan, Serdar Sahin, Cem Sulu, Hande Mefkure Ozkaya, Dildar Konukoglu, Fatma Ferda Kartufan, Fahrettin Kelestimur
Hormone and Metabolic Research.2022; 54(03): 153. CrossRef
COVID-19 and diabetes: Association intensify risk factors for morbidity and mortality
Prateek Sharma, Tapan Behl, Neelam Sharma, Sukhbir Singh, Ajmer Singh Grewal, Ali Albarrati, Mohammed Albratty, Abdulkarim M. Meraya, Simona Bungau
Biomedicine & Pharmacotherapy.2022; 151: 113089. CrossRef
The Relationship between COVID-19 and Hypothalamic–Pituitary–Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess—The CAPISCO International Expert Panel
Mojca Jensterle, Rok Herman, Andrej Janež, Wael Al Mahmeed, Khalid Al-Rasadi, Kamila Al-Alawi, Maciej Banach, Yajnavalka Banerjee, Antonio Ceriello, Mustafa Cesur, Francesco Cosentino, Massimo Galia, Su-Yen Goh, Sanjay Kalra, Peter Kempler, Nader Lessan,
International Journal of Molecular Sciences.2022; 23(13): 7326. CrossRef
WhatsApp-Based virtual consultation in clinical practice during COVID times: A prospective institutional study
RamakanthBhargav Panchangam, Pradeep Puthenveetil, SunilKumar Kota, Sabaretnam Mayilvaganan
Annals of African Medicine.2022; 21(2): 132. CrossRef
Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects
G. Lisco, A. De Tullio, E. Jirillo, V. A. Giagulli, G. De Pergola, E. Guastamacchia, V. Triggiani
Journal of Endocrinological Investigation.2021; 44(9): 1801. CrossRef
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19
Sang Youl Rhee, Jeongwoo Lee, Hyewon Nam, Dae-Sung Kyoung, Dong Wook Shin, Dae Jung Kim
Diabetes & Metabolism Journal.2021; 45(2): 251. CrossRef
COVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society
Cheol Ryong Ku, Kyong Yeun Jung, Chang Ho Ahn, Jun Sung Moon, Ju Hee Lee, Eun Heui Kim, Hyemi Kwon, Hee Kyung Kim, Sunghwan Suh, Sangmo Hong, Jeonghoon Ha, Eun Roh, Jin Hwa Kim, Mi-kyung Kim
Endocrinology and Metabolism.2021; 36(4): 757. CrossRef
Collateral Damage of the COVID‐19 Pandemic on Nutritional Quality and Physical Activity: Perspective from South Korea
Soo Lim, Hyunjung Lim, Jean‐Pierre Després
Obesity.2020; 28(10): 1788. CrossRef
Diabetes mellitus and COVID-19 in the post-acute phase patients - possible links with physical and rehabilitation medicine and balneotherapy
Constantin Munteanu, Diana-Loreta PĂUN, Alina-Maria ȘUȚĂ, Simin Aysel FLORESCU, Gelu ONOSE, Mihail Hoteteu
Balneo Research Journal.2020; 11(Vol.11, no): 350. CrossRef
Managing Diabetes During the COVID-19 Pandemic
John Doupis, Konstantinos Avramidis
European Endocrinology.2020; 16(2): 85. CrossRef
Independent Impact of Diabetes on the Severity of Coronavirus Disease 2019 in 5,307 Patients in South Korea: A Nationwide Cohort Study
Sun Joon Moon, Eun-Jung Rhee, Jin-Hyung Jung, Kyung-Do Han, Sung-Rae Kim, Won-Young Lee, Kun-Ho Yoon
Diabetes & Metabolism Journal.2020; 44(5): 737. CrossRef
SARS-CoV-2 (COVID-19) and the Endocrine System
Michelle D Lundholm, Caroline Poku, Nicholas Emanuele, Mary Ann Emanuele, Norma Lopez
Journal of the Endocrine Society.2020;[Epub] CrossRef

First
Prev
Page of 2
Next
Last

COVID-19 in EnM